Actively Recruiting
Efficacy of Upadacitinib After NECS in Vitiligo
Led by Jilin University · Updated on 2024-12-27
60
Participants Needed
1
Research Sites
234 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to investigate the efficacy of upadacitinib after NECS in participants with vitiligo. The main question it aims to answer is: whether the short time use of upadacitinib after NECS will improve NECS efficacy. Participants in the experimental group will receive upadacitinib after NECS, while Participants in the control group will receive NECS only.
CONDITIONS
Official Title
Efficacy of Upadacitinib After NECS in Vitiligo
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to sign informed consent
- Aged 18 to 60 years at the time of consent
- Diagnosed with non-segmented vitiligo
- Vitiligo area includes target flat lesions excluding hands, feet, perineum, lips, joints, perianal
- Total body surface area affected is 30% or less
- Vitiligo has been stable without new or expanding lesions for more than one year
- Women of childbearing potential willing to use effective contraception from consent through final follow-up
- Willing and able to attend all scheduled visits and follow study procedures
You will not qualify if you...
- Active skin conditions or infections that interfere with vitiligo assessment at screening
- Significant infection requiring hospitalization or treatment within one month before screening
- Infection with hepatitis B, hepatitis C, HIV, or syphilis
- Active or recently treated tuberculosis within the past year
- Liver dysfunction with elevated bilirubin or liver enzymes at screening
- Kidney impairment with eGFR below 45 mL/min or on dialysis at screening
- Current or past malignancy except treated nonmetastatic basal or squamous cell carcinoma
- Current thyroid disease or thyroid replacement therapy
- History of mental illness deemed unfit for study participation
- Pregnant or breastfeeding women
- Use of laser or phototherapy for vitiligo within 4 weeks before baseline
- Use of systemic or oral medications for vitiligo within 4 weeks before baseline
- Use of JAK inhibitors within 12 weeks or 5 half-lives before baseline
- Use of biologic agents within 12 weeks or 5 half-lives before baseline
- Participation in another clinical trial or treatment within 4 weeks before baseline
- Any other condition the investigator considers exclusionary
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Dermatology and Venerology, The First Hospital of Jilin University, No. 1 Xinmin Street
Changchun, Jilin, China, 130021
Actively Recruiting
Research Team
B
Bing Han
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here